Igor Odintsov, MD
Assistant Professor
Pathology
School of Medicine

Publications (43)

Top publication keywords:
HemangiosarcomaBiomarkers, TumorSoft Tissue NeoplasmsTelomere-Binding ProteinsGene AmplificationNeuregulin-1Gene DuplicationGerm-Line MutationVascular Endothelial Growth Factor Receptor-2Heart NeoplasmsLung NeoplasmsSarcoma, Clear CellCarcinoma, Non-Small-Cell LungGene FusionGene Rearrangement

• Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025 Pecci F, Agrawal P, Ross JS, Ricciuti B, Nakazawa S, Di Federico A, Aldea M, Garbo E, Santo V, Gariazzo E, Makarem M, Haradon D, Odintsov I, Baine M, Travis W, Yang SR, Ugalde Figueroa PA, Gray KD, …
• High-Grade Early-Onset Prostate Cancer: Assessment of TMPRSS2::ERG -Negative Tumors Suggests Low Frequency of Germline Alterations and a Pathogenic Role for HOXB13.
  The American journal of surgical pathology 2025 Maharjan D, Siegmund S, Michalova K, Odintsov I, Hornick JL, Nair V, Idrees MT, Collins K, Gordetsky JB, Osunkoya AO, Cheng L, Miyamoto H, Sangoi AR, Wu DJ, Ricci C, Mollica V, Raspollini MR, …
• MUC4-positive Fibroblastoma: A Distinctive Hyalinized Spindle Cell Neoplasm With Aberrant Nuclear Beta-catenin Expression and Frequent Biallelic Inactivation of APC.
  The American journal of surgical pathology 2025 Repetto F, Odintsov I, Sholl LM, Hornick JL, Anderson WJ
• Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report.
  JCO precision oncology 2025 Gariazzo E, Laaksonen S, Canty S, De Almeida GR, Odintsov I, Santo V, Garbo E, Pecci F, Aldea M, Oser MG, Sholl L, Sands JM, Ricciuti B
• Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
  Cancer discovery 2025 Nakazawa S, Pecci F, Odintsov I, Gazgalis D, Gottlieb FH, Ricciuti B, Zullo L, Alessi JV, Di Federico A, Aldea M, Garbo E, Gandhi MM, Saini A, Feng WW, Jiang J, Baldacci S, Facchinetti F, Makarem M, …

Show all (38 more) Hide

• Genetic correlates of malignancy in TFE3-rearranged PEComa: a series of 14 cases.
  Histopathology 2025 Papke DJ, Odintsov I, Mahadevan NR, Fletcher CD, Hanna J
• Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.
  Cancer discovery 2025 Febres-Aldana CA, Vojnic M, Odintsov I, Zhang T, Cheng R, Beach CZ, Lu D, Mattar MS, Gazzo AM, Gili L, Harshan M, Ameri A, Machnicki S, Xiao X, Lockwood WW, Zhou XY, Yao Q, Drilon A, Rekhtman N, Shah …
• Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 Alterations.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2025 Odintsov I, Papke DJ, George S, Padera RF, Hornick JL, Siegmund SE
• Malignant Giant Cell Tumor of Bone: A Clinicopathologic Series of 28 Cases Highlighting Genetic Differences Compared With Conventional, Atypical, and Metastasizing Conventional Tumors.
  The American journal of surgical pathology 2025 Papke DJ, Kovacs SK, Odintsov I, Hornick JL, Raskin KA, Newman ET, Lozano-Calderón S, Chebib I, Hung YP, Nielsen GP
• Odontogenic Myxoma Harbors Widespread Loss of Heterozygosity and Not Trisomies.
  The American journal of surgical pathology 2025 Odintsov I, Kleijn TG, Ryall ST, Ameline B, Dong F, Szuhai K, Baumhoer D, Dal Cin P, Cleven AHG, Papke DJ
• BRAF Gene Fusions in Melanoma: First Kinase Domain Duplication, New Fusion Partners, and Clinical Outcomes.
  The American journal of surgical pathology 2025 Odintsov I, Davis D, Pissaloux D, Tirode F, de la Fouchardiere A, Hanna J
• Clear Cell Stromal Tumor of the Lung: Clinicopathologic, Immunohistochemical, and Molecular Characterization of Eight Cases.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2024 Odintsov I, Isaacson A, Fritchie KJ, Hung YP, Khoshnoodi P, Sholl LM, Fletcher CDM, Anderson WJ
• HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Zhang T, Febres-Aldana CA, Liu Z, Dix JM, Cheng R, Dematteo RG, Lui AJW, Khodos I, Gili L, Mattar MS, Lisanti J, Kwong C, Linkov I, Tipping MJ, de Stanchina E, Odintsov I, Ladanyi M, Somwar R
• Epithelioid Fibrous Histiocytoma Is on a Continuum With Superficial ALK -rearranged Myxoid Spindle Cell Neoplasm : A Clinicopathologic Series of 35 Cases Including Alternate RET and NTRK3 Fusions.
  The American journal of surgical pathology 2024 DeSimone MS, Odintsov I, Tsai HK, Dickson BC, Alomari AK, Hornick JL, Fletcher CDM, Papke DJ
• Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification.
  JCO precision oncology 2024 Elkrief A, Odintsov I, Smith RS, Vojnic M, Hayashi T, Khodos I, Markov V, Liu Z, Lui AJW, Bloom JL, Offin MD, Rudin CM, de Stanchina E, Riely GJ, Somwar R, Ladanyi M
• Preclinical evaluation of targeted therapies for central nervous system metastases.
  Disease models & mechanisms 2024 Pfeil AJ, Hale JD, Zhang TS, Wakayama K, Miyazaki I, Odintsov I, Somwar R
• Myxoid Inflammatory Myofibroblastic Sarcoma: Clinicopathologic Analysis of 25 Cases of a Distinctive Sarcoma With Deceptively Bland Morphology and Aggressive Clinical Behavior.
  The American journal of surgical pathology 2024 Papke DJ, Odintsov I, Dickson BC, Nucci MR, Agaimy A, Fletcher CDM
• A visual-language foundation model for computational pathology.
  Nature medicine 2024 Lu MY, Chen B, Williamson DFK, Chen RJ, Liang I, Ding T, Jaume G, Odintsov I, Le LP, Gerber G, Parwani AV, Zhang A, Mahmood F
• Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023 Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, Sholl LM
• Prognostic and predictive biomarkers in non-small cell lung carcinoma.
  Pathology 2023 Odintsov I, Sholl LM
• Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
  Nature cancer 2023 Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, …
• Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
  Nature cancer 2023 Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, …
• HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023 Udagawa H, Nilsson MB, Robichaux JP, He J, Poteete A, Jiang H, Heeke S, Elamin YY, Shibata Y, Matsumoto S, Yoh K, Okazaki S, Masuko T, Odintsov I, Somwar R, Ladanyi M, Goto K, Heymach JV
• Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis.
  The American journal of surgical pathology 2023 Odintsov I, Dong F, Guenette JP, Fritchie KJ, Jo VY, Fletcher CDM, Papke DJ
• Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023 Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga…
• Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023 Lo YC, Bauer AH, Odintsov I, Siegmund SE, Sholl LM, Dong F
• Primary Clear Cell Sarcoma of Bone: Clinicopathologic Study of a Rare Presentation.
  The American journal of surgical pathology 2022 Odintsov I, Jagannathan JP, Al-Ibraheemi A, Selig MK, Newman ET, Fletcher CDM, Nielsen GP, Hornick JL
• MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
  Molecular cancer research : MCR 2022 Iyer SR, Odintsov I, Schoenfeld AJ, Siau E, Mattar MS, de Stanchina E, Khodos I, Drilon A, Riely GJ, Ladanyi M, Somwar R, Davare MA
• Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
  Cancer discovery 2022 Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, …
• Corrigendum: Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.
  Cold Spring Harbor molecular case studies 2022 Choo F, Odintsov I, Nusser K, Nicholson K, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA
• CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.
  Cancer research 2022 Odintsov I, Ortiz MV, Khodos I, Mattar MS, Lui AJW, Kohsaka S, de Stanchina E, Bender JLG, Ladanyi M, Somwar R
• Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.
  Cold Spring Harbor molecular case studies 2022 Choo F, Odintsov I, Nusser K, Nicholson KS, Davis L, Corless CL, Stork L, Somwar R, Ladanyi M, Davis JL, Davare MA
• Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling.
  Disease models & mechanisms 2022 Smith RS, Odintsov I, Liu Z, Lui AJ, Hayashi T, Vojnic M, Suehara Y, Delasos L, Mattar MS, Hmeljak J, Ramirez HA, Shaw M, Bui G, Hartono AB, Gladstone E, Kunte S, Magnan H, Khodos I, De Stanchina E, …
• Determination of biological behavior of solitary fibrous tumors: correlation of expression of Ki-67, TPX2 and TERT mRNA subunit level and NAB2-STAT6 fusion compared to morphological aspects of SFTs.
  Neoplasma 2021 Krsková L, Odintsov I, Fabián O, Hroudová P, Mrhalová M
• Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Odintsov I, Mattar MS, Lui AJW, Offin M, Kurzatkowski C, Delasos L, Khodos I, Asher M, Daly RM, Rekhtman N, de Stanchina E, Ganji G, Ladanyi M, Somwar R
• The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, Kurth RI, Sisso EM, Vojnic M, Khodos I, Mattar MS, de Stanchina E, Leland SM, Ladanyi M, Somwar R
• ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development.
  JCO oncology practice 2021 Odintsov I, Somwar R, Ladanyi M, Drilon A
• NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
  Communications biology 2020 Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA
• RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
  Disease models & mechanisms 2020 Hayashi T, Odintsov I, Smith RS, Ishizawa K, Liu AJW, Delasos L, Kurzatkowski C, Tai H, Gladstone E, Vojnic M, Kohsaka S, Suzawa K, Liu Z, Kunte S, Mattar MS, Khodos I, Davare MA, Drilon A, Cheng E, …
• Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Ogura K, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, Bowman AS, Mattar MS, Khodos I, de Stanchina E, Jungbluth A, Asher M, Odintsov I, Hartono AB, LaQuaglia MP, Slotkin E, Pratilas …
• Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas.
  Oncology letters 2020 Vodicka P, Krskova L, Odintsov I, Krizova L, Sedlackova E, Schutzner J, Zamecnik J
• Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.
  JCO precision oncology 2019 Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M
• A blast from the past: ROS1 on the brain.
  Oncotarget 2019 Odintsov I, Somwar R, Davare MA